Home
>
US Stocks
>
Novavax, Inc.
Novavax, Inc.
NVAX

Novavax, Inc. (NVAX)

$138.6839.79%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
140.5
Today Low/High
136.86 / 143.17
52 Week Low/High
$76.59 / $331.68
P/E ratio
-18.3931
Market Cap
$17.47B

Company Details

Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
Organisation
Novavax, Inc.
Headquaters
Gaithersburg, Maryland, US
Employees
791
Industry
Health Technology
CEO
Stanley Erck
Company Financials
  • Annual P&L
  • Quarterly P&L

Discover more

Frequently Asked Questions

What is Novavax, Inc. (NVAX) share price today?

Can Indians buy Novavax, Inc. (NVAX) shares?

How can I buy Novavax, Inc. (NVAX) shares from India?

Can Fractional shares of Novavax, Inc. (NVAX) be purchased?

What are the documents required to start investing in Novavax, Inc. (NVAX) stocks?

We are a SEBI registered investement advisor